- Home
- PNTG vs CGEN Comparison
PNTG vs CGEN Comparison
Compare PNTG & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNTG
- CGEN
- Stock Information
- Founded
- PNTG 2019
- CGEN 1993
- Country
- PNTG United States
- CGEN Israel
- Employees
- PNTG N/A
- CGEN N/A
- Industry
- PNTG Medical/Nursing Services
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PNTG Health Care
- CGEN Health Care
- Exchange
- PNTG Nasdaq
- CGEN Nasdaq
- Market Cap
- PNTG 930.2M
- CGEN 134.3M
- IPO Year
- PNTG N/A
- CGEN 2000
- Fundamental
- Price
- PNTG $26.46
- CGEN $1.65
- Analyst Decision
- PNTG Buy
- CGEN Strong Buy
- Analyst Count
- PNTG 4
- CGEN 1
- Target Price
- PNTG $38.25
- CGEN $4.00
- AVG Volume (30 Days)
- PNTG 227.5K
- CGEN 470.1K
- Earning Date
- PNTG 02-26-2025
- CGEN 11-12-2024
- Dividend Yield
- PNTG N/A
- CGEN N/A
- EPS Growth
- PNTG 62.21
- CGEN N/A
- EPS
- PNTG 0.68
- CGEN 0.02
- Revenue
- PNTG $652,302,000.00
- CGEN $59,852,000.00
- Revenue This Year
- PNTG $29.15
- CGEN $57.27
- Revenue Next Year
- PNTG $17.91
- CGEN N/A
- P/E Ratio
- PNTG $38.66
- CGEN $85.40
- Revenue Growth
- PNTG 24.58
- CGEN 698.03
- 52 Week Low
- PNTG $14.12
- CGEN $1.35
- 52 Week High
- PNTG $37.13
- CGEN $3.03
- Technical
- Relative Strength Index (RSI)
- PNTG 28.94
- CGEN 56.57
- Support Level
- PNTG $25.89
- CGEN $1.47
- Resistance Level
- PNTG $27.14
- CGEN $1.65
- Average True Range (ATR)
- PNTG 0.90
- CGEN 0.10
- MACD
- PNTG -0.11
- CGEN 0.00
- Stochastic Oscillator
- PNTG 12.54
- CGEN 80.80
About PNTG The Pennant Group Inc.
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.